Innovation in insulin delivery

Some are on the verge of commercializing transformational approaches for patients.

We spoke with the executives of Oramed Pharmaceuticals and Novo Nordisk to get low information on the research developments of both companies in terms of promoting insulin delivery to patients with diabetes, reducing the burden of disease management for such people.

Oral Insulin: The Holy Grail?

Oramed is looking to develop oral diabetes medications that are currently injectable.

Its patented lead candidate, ORMD-0801, could become the first commercial oral insulin capsule to treat diabetes.

Nada Kidron, CEO of Oramed Pharmaceuticals, announced the company’s goals for 2022 in this regard:

“This year will be very exciting for Oramed and Oral Insulins as we look forward to completing the registration of our Phase 3 Oral Insulin Test for Type 2 Diabetes (T2D) and share ORA-D-013 data. -1 in the 4th quarter of 2022. Taking care of

“Currently, our clinical focus is on T2D for oral insulin, and we aim for the end of next year to apply for BLA.”Taking care of

Also this year, the company expects to complete registration for NASH’s oral insulin trials with initial data.

Oral insulin has a number of potential benefits, Kidron explained, including a more natural way of giving birth.

«Oramed Oral Insulin – recombinant human insulin – unlike injectable insulin, mimics the body’s endogenous insulin and regulates liver glucose levels. Also, with oral insulin pills, patient adherence is likely to be much higher – studies have shown that people prefer a pill to an injection. Taking care of


Leave a Comment